D. Paillotin

828 total citations
24 papers, 591 citations indexed

About

D. Paillotin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, D. Paillotin has authored 24 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in D. Paillotin's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (5 papers). D. Paillotin is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (5 papers). D. Paillotin collaborates with scholars based in France, Cameroon and Luxembourg. D. Paillotin's co-authors include G. Robinet, H. Léna, H. Bérard, P. Thomas, I. Monnet, R. Gervais, M. Pérol, Fabrice Barlési, Abdesslam Chajara and J. Hureaux and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and CHEST Journal.

In The Last Decade

D. Paillotin

23 papers receiving 575 citations

Peers

D. Paillotin

PRM

ONCOL

GENET

EPIDE

Peter Farha United States

L.J. Djuric Serbia

C. Labbé-Devilliers France

Naoki Omachi Japan

Gilles Quéré France

Melek Tuğçe Yılmaz Türkiye

Yael Steinberg‐Silman Israel

F. Thillays France

Maria Ausilia Teriaca Italy

Mari Aso Japan

Peter Farha United States

D. Paillotin

272 ×0.5

PRM

340 ×0.7

ONCOL

22 ×0.2

GENET

115 ×1.3

EPIDE

81 ×1.3

Citations per year, relative to D. Paillotin D. Paillotin (= 1×) peers Peter Farha

Countries citing papers authored by D. Paillotin

Since Specialization

Citations

This map shows the geographic impact of D. Paillotin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Paillotin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Paillotin more than expected).

Fields of papers citing papers by D. Paillotin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Paillotin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Paillotin. The network helps show where D. Paillotin may publish in the future.

Co-authorship network of co-authors of D. Paillotin

This figure shows the co-authorship network connecting the top 25 collaborators of D. Paillotin. A scholar is included among the top collaborators of D. Paillotin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Paillotin. D. Paillotin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barlési, Fabrice, R. Gervais, H. Léna, et al.. (2011). Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Annals of Oncology. 22(11). 2466–2470. 181 indexed citations

Vergnenègre, A., R. Corre, H. Bérard, et al.. (2010). Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. Journal of Thoracic Oncology. 6(1). 161–168. 27 indexed citations

Marie, I., et al.. (2010). Syndrome sclérodermiforme paranéoplasique. Revue des Maladies Respiratoires. 27(3). 251–256. 7 indexed citations

Robinet, G., Fabrice Barlési, R. Gervais, et al.. (2010). Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01).. Journal of Clinical Oncology. 28(15_suppl). 7595–7595. 1 indexed citations

Chouaïd, C., I. Monnet, C. Locher, et al.. (2010). PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504). Value in Health. 13(7). A267–A267. 2 indexed citations

Vergnenègre, A., H. Bérard, D. Paillotin, et al.. (2009). PCN125 AN ECONOMICAL, RANDOMIZED, MULTICENTER PHASE III TRIAL OF SECOND LINE TREATMENT FOR NON SMALL CELL LUNG CANCER (NSCLC) COMPARING DOCETAXEL VERSUS PEMETREXED: GFPC (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE) 05–06 STUDY. Value in Health. 12(7). A281–A281. 1 indexed citations

Fournel, P., C. Chouaïd, J. Letreut, et al.. (2007). An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study. Critical Reviews in Oncology/Hematology. 64(1). 73–81. 16 indexed citations

Gervais, R., et al.. (2007). Étude de phase 2, randomisée, évaluant une polychimiothérapie orale (CCNU, Cyclophosphamide, étoposide) et une polychimiothérapie intraveineuse dans les cancers bronchiques à petites cellules en seconde ligne en rechute (essai GFPC0501). Revue des Maladies Respiratoires. 24(5). 653–658. 2 indexed citations

Bérard, H., et al.. (2005). Multicenter Phase II Trial of Carboplatin/Vinorelbine in Elderly Patients with Advanced Non–Small-Cell Lung Cancer–Efficacy and Impact on Quality of Life: Groupe Français de Pneumo-Cancérologie Study 9902. Clinical Lung Cancer. 7(2). 114–120. 9 indexed citations

10.

Vergnenègre, A., Casey L. Daniel, H. Léna, et al.. (2004). Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. Lung Cancer. 47(3). 395–404. 12 indexed citations

11.

Robinet, G., P. Thomas, Jean-Luc Breton, et al.. (2001). Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Annals of Oncology. 12(1). 59–67. 198 indexed citations

12.

Thomas, P., O. Castelnau, D. Paillotin, et al.. (2001). Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Français de Pneumo-Cancérologie Study. Journal of Clinical Oncology. 19(5). 1320–1325. 31 indexed citations

13.

Robinet, G., P. Thomas, M. Pérol, et al.. (2000). [Phase II study of docetaxel in inoperable advanced non small cell lung cancer].. PubMed. 87(3). 253–8. 9 indexed citations

14.

Robinet, G., P. Thomas, M. Pérol, et al.. (2000). [Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].. PubMed. 17(1). 83–9. 8 indexed citations

15.

Vergnenègre, A., Paul S. Thomas, G. Robinet, et al.. (1999). [High-dose ifosfamide in patients with stage IV non-small cell lung cancer: phase II trial from the Groupe français de pneumo-cancérologie (GFPC)].. PubMed. 86(12). 1017–21. 4 indexed citations

16.

Urban, T., C Chastang, F. Vaylet, et al.. (1998). Prognostic Significance of Supraclavicular Lymph Nodes in Small Cell Lung Cancer. CHEST Journal. 114(6). 1538–1541. 13 indexed citations

17.

Thomas, P., J P Kleisbauer, G. Robinet, et al.. (1997). Carboplatin as radiosensitizer in non-small cell lung cancer after cisplatin containing chemotherapy.. Lung Cancer. 18(1). 71–81. 2 indexed citations

18.

Pérol, M., J C Guérin, P. Thomas, et al.. (1996). Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. Lung Cancer. 14(1). 119–134. 21 indexed citations

19.

Collery, Philippe, Hervé Millart, D. Paillotin, et al.. (1995). Dose optimization of gallium chloride, orally administered, in combination with platinum compounds.. PubMed. 14(6A). 2299–306. 1 indexed citations

20.

Girault, Christophe, et al.. (1993). [Mediastinal bronchogenic cyst associated with a multiple malformation syndrome].. PubMed. 10(4). 371–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact